Trial Profile

Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Cancer Patients Undergoing Surgery

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 28 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabiralizumab (Primary) ; HuMax IL8 (Primary) ; Nivolumab (Primary)
Indications Head and neck cancer; Squamous cell cancer
Focus Adverse reactions
Acronyms Spark2

Most Recent Events

14 May 2026 Planned End Date changed from 1 Sep 2026 to 1 Nov 2030.
14 May 2026 Planned primary completion date changed from 1 Apr 2026 to 1 Apr 2027.
18 Dec 2025 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com